ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

166
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
bullishIndegene
03 May 2024 10:29

Indegene IPO - Marquee Clients, Strong Track Record, Decent Valuation

Indegene Limited (1864095D IN) is looking to raise US$220m in its India IPO, via selling a mix of primary and secondary shares.

Logo
465 Views
Share
bullishIndegene
02 May 2024 11:27

Indegene Pre-IPO - RHP Updates - Client Base Continued to Grow, and Margins Have Begun Stabilizing

Indegene Limited (1864095D IN) is looking to raise about US$220m in its upcoming India IPO. We looked at the firm’s past performance in an earlier...

Logo
672 Views
Share
02 Apr 2024 20:06Broker

Axis Research Scorecard Report for March 2024

Pick of the Week (PoW): POW calls delivered an astounding monthly strike rate of 92% in Mar’24. Calls that successfully achieved their target were...

Logo
272 Views
Share
02 Apr 2024 03:16Broker

Axis Top Picks for the Month of April 2024

AxisTop Picks basket delivered impressive returns of 46% in FY24, against the 28.6% return posted by the benchmark Nifty 50, implying a commendable...

Logo
306 Views
Share
bullishMankind Pharma
25 Mar 2024 21:42

Mankind Pharma Placement - Well Flagged, past Deals Have Done Well but Its Expensive

ChrysCap is looking to raise around US$295m via selling a 2.8% stake in Mankind Pharma. In this note, we talk about the deal dynamics.

Logo
298 Views
Share
x